JP2019521976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521976A5 JP2019521976A5 JP2018564389A JP2018564389A JP2019521976A5 JP 2019521976 A5 JP2019521976 A5 JP 2019521976A5 JP 2018564389 A JP2018564389 A JP 2018564389A JP 2018564389 A JP2018564389 A JP 2018564389A JP 2019521976 A5 JP2019521976 A5 JP 2019521976A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- composition
- physiological buffer
- vegf
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 238000009472 formulation Methods 0.000 claims 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- 208000010125 myocardial infarction Diseases 0.000 claims 9
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 102000001974 Hyaluronidases Human genes 0.000 claims 1
- 108050009363 Hyaluronidases Proteins 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 239000011258 core-shell material Substances 0.000 claims 1
- 210000003748 coronary sinus Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002612 dispersion medium Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- -1 isotonics Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049671A JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2022171389A JP2023011733A (ja) | 2016-06-07 | 2022-10-26 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346979P | 2016-06-07 | 2016-06-07 | |
| US62/346,979 | 2016-06-07 | ||
| US201662411091P | 2016-10-21 | 2016-10-21 | |
| US62/411,091 | 2016-10-21 | ||
| US201662432005P | 2016-12-09 | 2016-12-09 | |
| US62/432,005 | 2016-12-09 | ||
| PCT/US2017/036188 WO2017214175A1 (en) | 2016-06-07 | 2017-06-06 | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049671A Division JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521976A JP2019521976A (ja) | 2019-08-08 |
| JP2019521976A5 true JP2019521976A5 (enExample) | 2020-10-01 |
| JP6859369B2 JP6859369B2 (ja) | 2021-04-14 |
Family
ID=59270113
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564389A Active JP6859369B2 (ja) | 2016-06-07 | 2017-06-06 | Ｖｅｇｆ−ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2021049671A Active JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2022171389A Pending JP2023011733A (ja) | 2016-06-07 | 2022-10-26 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049671A Active JP7167226B2 (ja) | 2016-06-07 | 2021-03-24 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
| JP2022171389A Pending JP2023011733A (ja) | 2016-06-07 | 2022-10-26 | Ｖｅｇｆ－ａポリペプチドをコードする改変ｒｎａ、製剤、およびそれに関連する使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866475B2 (enExample) |
| EP (2) | EP3971204A1 (enExample) |
| JP (3) | JP6859369B2 (enExample) |
| KR (4) | KR102494499B1 (enExample) |
| CN (2) | CN116606861A (enExample) |
| AU (2) | AU2017277277B2 (enExample) |
| CA (1) | CA3026500A1 (enExample) |
| CY (1) | CY1124667T1 (enExample) |
| DK (1) | DK3464338T3 (enExample) |
| ES (1) | ES2895421T3 (enExample) |
| HR (1) | HRP20211569T1 (enExample) |
| HU (1) | HUE056055T2 (enExample) |
| IL (1) | IL263370A (enExample) |
| LT (1) | LT3464338T (enExample) |
| MA (1) | MA45172B1 (enExample) |
| MX (1) | MX2018015110A (enExample) |
| PL (1) | PL3464338T3 (enExample) |
| PT (1) | PT3464338T (enExample) |
| RS (1) | RS62556B1 (enExample) |
| RU (1) | RU2756313C2 (enExample) |
| SG (2) | SG11201810816QA (enExample) |
| SI (1) | SI3464338T1 (enExample) |
| SM (1) | SMT202100586T1 (enExample) |
| TW (2) | TWI752036B (enExample) |
| WO (1) | WO2017214175A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3971204A1 (en) | 2016-06-07 | 2022-03-23 | Modernatx, Inc. | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto |
| US11628227B2 (en) * | 2017-07-05 | 2023-04-18 | Wisconsin Alumni Research Foundation | Mineral coated microparticles for gene delivery in chronic wound therapy |
| DK3703658T3 (da) | 2017-10-31 | 2022-07-18 | Astrazeneca Ab | Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid |
| US20220226243A1 (en) * | 2019-05-08 | 2022-07-21 | Astrazeneca Ab | Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same |
| JP7345888B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| WO2023061985A2 (en) * | 2021-10-12 | 2023-04-20 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
| WO2023084013A1 (en) * | 2021-11-12 | 2023-05-19 | Modernatx, Inc. | Compositions comprising modified rna encoding vegf-a and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| WO2006086798A2 (en) | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Compositions and methods involving mda-7 for the treatment of cancer |
| JP5705127B2 (ja) | 2008-12-03 | 2015-04-22 | アモーサイト インコーポレイテッド | 梗塞領域灌流改善組成物および血管損傷修復の方法 |
| MX2011005912A (es) * | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular. |
| WO2011069529A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| WO2012103985A2 (en) | 2010-12-16 | 2012-08-09 | Steve Pascolo | Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| WO2012138453A1 (en) | 2011-04-03 | 2012-10-11 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
| HRP20220717T1 (hr) | 2011-12-16 | 2022-07-22 | Modernatx, Inc. | Modificirani pripravci mrna |
| RU2014129863A (ru) | 2011-12-21 | 2016-02-10 | Модерна Терапьютикс, Инк. | Способы повышения жизнеспособности или увеличения продолжительности жизни органа или экспланта органа |
| US20140275229A1 (en) * | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| JP6189415B2 (ja) | 2012-04-02 | 2017-08-30 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド |
| US9663564B2 (en) | 2013-03-15 | 2017-05-30 | The Regents Of The University Of California | Vectors and methods to treat ischemia |
| EP2971010B1 (en) * | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| KR102354389B1 (ko) * | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| EP3094647A1 (en) | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
| WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| ES2969082T3 (es) | 2015-09-17 | 2024-05-16 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| EP3971204A1 (en) | 2016-06-07 | 2022-03-23 | Modernatx, Inc. | Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| MX389934B (es) | 2016-12-09 | 2025-03-20 | Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V | Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos. |
| DK3703658T3 (da) | 2017-10-31 | 2022-07-18 | Astrazeneca Ab | Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid |
| EP3965797A1 (en) | 2019-05-08 | 2022-03-16 | AstraZeneca AB | Compositions for skin and wounds and methods of use thereof |
-
2017
- 2017-06-06 EP EP21186195.0A patent/EP3971204A1/en not_active Withdrawn
- 2017-06-06 RS RS20211280A patent/RS62556B1/sr unknown
- 2017-06-06 KR KR1020227008509A patent/KR102494499B1/ko active Active
- 2017-06-06 MX MX2018015110A patent/MX2018015110A/es unknown
- 2017-06-06 CN CN202310693718.2A patent/CN116606861A/zh active Pending
- 2017-06-06 EP EP17734885.1A patent/EP3464338B1/en active Active
- 2017-06-06 DK DK17734885.1T patent/DK3464338T3/da active
- 2017-06-06 PL PL17734885T patent/PL3464338T3/pl unknown
- 2017-06-06 HR HRP20211569TT patent/HRP20211569T1/hr unknown
- 2017-06-06 MA MA45172A patent/MA45172B1/fr unknown
- 2017-06-06 SI SI201730935T patent/SI3464338T1/sl unknown
- 2017-06-06 PT PT177348851T patent/PT3464338T/pt unknown
- 2017-06-06 AU AU2017277277A patent/AU2017277277B2/en not_active Ceased
- 2017-06-06 LT LTEPPCT/US2017/036188T patent/LT3464338T/lt unknown
- 2017-06-06 SG SG11201810816QA patent/SG11201810816QA/en unknown
- 2017-06-06 CN CN201780048447.8A patent/CN109790207B/zh active Active
- 2017-06-06 RU RU2018147229A patent/RU2756313C2/ru active
- 2017-06-06 KR KR1020197000227A patent/KR102376245B1/ko not_active Expired - Fee Related
- 2017-06-06 WO PCT/US2017/036188 patent/WO2017214175A1/en not_active Ceased
- 2017-06-06 ES ES17734885T patent/ES2895421T3/es active Active
- 2017-06-06 KR KR1020237003204A patent/KR102552543B1/ko active Active
- 2017-06-06 JP JP2018564389A patent/JP6859369B2/ja active Active
- 2017-06-06 CA CA3026500A patent/CA3026500A1/en active Pending
- 2017-06-06 HU HUE17734885A patent/HUE056055T2/hu unknown
- 2017-06-06 KR KR1020237022229A patent/KR20230107891A/ko not_active Ceased
- 2017-06-06 SM SM20210586T patent/SMT202100586T1/it unknown
- 2017-06-06 SG SG10202012175YA patent/SG10202012175YA/en unknown
- 2017-06-06 US US16/305,224 patent/US11866475B2/en active Active
- 2017-06-07 TW TW106118838A patent/TWI752036B/zh not_active IP Right Cessation
- 2017-06-07 TW TW110145699A patent/TWI818375B/zh not_active IP Right Cessation
-
2018
- 2018-11-29 IL IL263370A patent/IL263370A/en unknown
-
2021
- 2021-03-24 JP JP2021049671A patent/JP7167226B2/ja active Active
- 2021-10-14 CY CY20211100889T patent/CY1124667T1/el unknown
-
2022
- 2022-10-26 JP JP2022171389A patent/JP2023011733A/ja active Pending
-
2023
- 2023-07-28 AU AU2023208200A patent/AU2023208200A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521976A5 (enExample) | ||
| TWI480069B (zh) | 用以改善心肌梗塞之醫藥組成物 | |
| HRP20211569T1 (hr) | Modificirana rna koja kodira vegf-a polipeptide, formulacije, i upotrebe koje se na njih odnose | |
| WO2006121532A3 (en) | Treatment for heart disease | |
| US20070093748A1 (en) | Methods and systems for treating injured cardiac tissue | |
| AU2019237720B2 (en) | Cardiac targeting agent comprising tannic acid | |
| JP2019206562A5 (enExample) | ||
| WO2022076556A3 (en) | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 | |
| JP2023171773A (ja) | 心臓機能を改善するための組成物および方法 | |
| JP2010163457A (ja) | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 | |
| CN101310766B (zh) | 神经调节蛋白的新用途 | |
| KR20180044235A (ko) | 조직 병변 치료용 조성물 | |
| CN104862281A (zh) | 表达bFGF和PDGF-BB的重组载体修饰的间充质干细胞及其制备方法和用途 | |
| Fazel et al. | Current status of cellular therapy for ischemic heart disease | |
| EA009390B1 (ru) | Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом | |
| Takehara | Cell therapy for cardiovascular regeneration | |
| Bahramian et al. | The effects of exercise training intensity on the expression of C/EBPβ and CITED4 in rats with myocardial infarction | |
| Aceves et al. | Autologous CXCR4+ hematopoietic stem cells injected into the scar tissue of chronic myocardial infarction patients normalizes tissue contractility and perfusion | |
| JP2015061536A5 (enExample) | ||
| JP2005206544A (ja) | 筋肉再生剤 | |
| RU2250772C1 (ru) | Способ лечения неоперабельных кардиологических больных | |
| CN103239714B (zh) | 用于治疗缺血性疾病的蛋白质及药物组合物 | |
| WO2022135278A1 (zh) | Azd3965药物的新用途 | |
| RU2822010C1 (ru) | Способ терапии сердечно-сосудистого заболевания | |
| WO2012138043A2 (en) | Therapeutic composition containing endothelin as an active component |